Biocon Ltd.

NSE: BIOCON | BSE: 532523 | ISIN: INE376G01013 | Industry: Biotechnology
| Mid-range Performer
356.9500 -1.25 (-0.35%)
NSE Oct 17, 2025 12:04 PM
Volume: 590.6K
 

logo
Biocon Ltd.
20 Jul 2017
356.95
-0.35%
Axis Direct
USFDA's Advisory Committee (ODAC) unanimously voted 16-0 in favor of approval of Biocon/ Mylan's MYL-1401O, biosimilar Trastuzumab (Herceptin) for all indications. It determined MYL-1401O is highly similar to Herceptin. We believe positive ODAC ruling paves way for the approval in US (albeit GMP..
Biocon Ltd. has an average target of 354.40 from 5 brokers.
More from Biocon Ltd.
Recommended